Steroids versus other immune modulators in the management of allergic dermatoses

Current Opinion in Allergy and Clinical Immunology

Volumn 6, Issue 5, 2006, Pages 345-354

  Abramovits, William ^a,b   Perlmutter, Amy ^b  

^a BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^b Texas Dermatology Associates PA   (United States)

Author keywords

Allergic dermatitis; Atopic; Eczema; Itch; Therapy

Indexed keywords

ANTIBIOTIC AGENT; ANTIHISTAMINIC AGENT; ANTIINFLAMMATORY AGENT; ANTIPRURITIC AGENT; AZATHIOPRINE; CALCINEURIN INHIBITOR; CERAMIDE; CHOLESTEROL; CORTICOSTEROID; CYCLOSPORIN; DOXEPIN; GAMMA INTERFERON; GLYCYRRHETINIC ACID; IMMUNOGLOBULIN E ANTIBODY; LIDOCAINE; METHOTREXATE; MIRTAZAPINE; MONTELUKAST; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NALTREXONE; PALMIDROL; PIMECROLIMUS; PRAMOCAINE; RETINOID; STEROID; TACROLIMUS; UNINDEXED DRUG; VITIS VINIFERA EXTRACT; ZAFIRLUKAST; ZILEUTON;

ATOPIC DERMATITIS; CANCER RISK; CLINICAL PRACTICE; DRUG EFFICACY; ECZEMA; HUMAN; IMMUNOMODULATION; PHOTOTHERAPY; PRIORITY JOURNAL; PRURITUS; REVIEW; SKIN ALLERGY; TISSUE REPAIR;

ADRENAL CORTEX HORMONES; ANTI-INFECTIVE AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BIOLOGICAL RESPONSE MODIFIERS; CALCINEURIN; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOSUPPRESSIVE AGENTS; SKIN DISEASES;

EID: 33748519879     PISSN: 15284050     EISSN: 14736322     Source Type: Journal    
DOI: 10.1097/01.all.0000244795.41357.6e     Document Type: Review

References (162)

1. Abramovits W. A clinician's paradigm in the treatment of atopic dermatitis. J Am Acad Dermatol 2005; 53:S70-S77. A thorough presentation illustrating the most effective ways to manage atopic dermatitis, by integrating preventive measures, education, systemic agents, phototherapy, and topicals into a clinical paradigm.
2. Schwarzer G, Bassler D, Mitra A, et al. Ketotifen alone or as additional medication for long-term control of asthma and wheeze in children. Cochrane Database Syst Rev 2004; 1:CD001384.
3. Leung DYM, Hanifin JM, Charlesworth EN. Disease management of atopic dermatitis: a practice parameter. Ann Allergy Asthma Immunol 1997; 79:197-211.
4. Abramovits W, Goldstein A, Stevenson L. Changing paradigms in dermatology: topical immunomodulators within a permutational paradigm for the treatment of atopic and eczematous dermatitis. Clin Dermatol 2003; 21:383-392.
5. Klein PA, Clark RA. An evidence-based review of the efficacy of antihistamines in relieving pruritus in atopic dermatitis. Arch Dermatol 1999; 135:1522-1525.
6. Beltrani VS. Suggestions regarding a more appropriate understanding of atopic dermatitis. Curr Opin Allergy Clin Immunol 2005; 5:413-418.
7. Hundley J, Yosipovitch G. Mirtazapine for reducing nocturnal itch in patients with chronic pruritus: a pilot study. J Am Acad Dermatol 2004; 50:889-891.
8. Greaves MW. Itch in systemic disease: therapeutic options. Dermatol Ther 2005; 18:323-327. A discussion of the various mechanisms of itch and how they correlate to different pruritic conditions, with additional explanation on the therapeutic approach.
9. Smith PF, Corelli RL. Doxepin in the management of pruritus associated with allergic cutaneous reactions. Ann Pharmacother 1997; 31:633-635.
10. Nowak MA, Tsoukas MM, DeImus FA, et al. Generalized pruritus without primary lesions Differential diagnosis and approach to treatment. Postgrad Med 2000; 107:41-42; 45-6.
11. Lakshmanan M, Mion LC, Frengley JD. Effective low-dose tricyclic antidepressant treatment for depressed geriatric rehabilitation patients. A double-blind study. J Am Geriatr Soc 1986; 34:421-426.
12. Tennyson H, Levine N. Neurotropic and psychotropic drugs in dermatology. Dermatol Clin 2001; 19:179-197.
13. Heyer GR, Hornstein OP. Recent studies of cutaneous nocioception in atopic and nonatopic subjects. J Dermatol 1999; 26:77-86.
14. Metze D, Reimann S, Beissert S, et al. Efficacy and safety of naltrexone, an oral opiate receptor antagonist, in the treatment of pruritus in internal dermatological diseases. J Am Acad Dermatol 1999; 41:533-539.
15. Stander S, Steinhoff M. Pathophysiology of pruritus in atopic dermatitis: an overview [review]. Exp Dermatol 2002; 11:12-24.
16. Heyer G, Dotzer M, Diepgen TL, Handwerker HO. Opiate and H1 antagonist effects on histamine induced pruritus and alloknesis. Pain 1997; 73:239-243.
17. Heyer G, Groene D, Martus P. Efficacy of naltrexone on acetylcholineinduced alloknesis in atopic eczema. Exp Dermatol 2002; 11:448-455.
18. Bornhovd E, Burgdorf WH, Wollenberg A. Macrolactam immunomodulators for topical treatment of inflammatory skin diseases. J Am Acad Dermatol 2001; 45:736-743.
19. Gottlieb, Alice B. Therapeutic options in the treatment of psoriasis and atopic dermatitis. J Am Acad Dermatol 2005; 53:S3-S16. A summary of the available therapy for treatment of psoriasis and atopic dermatitis, including how the mechanism of action for each of these agents relates to the disease pathogenesis.
20. Hanifin JM, Cooper KD, Ho VC, et al. Guidelines of care for atopic dermatitis, developed in accordance with the American Academy of Dermatology(AAD)/American Academy of Dermatology Association: 'Administrative Regulations for Evidence-Based Clinical Practice Guidelines'. J Am Acad Dermatol 2004; 50:391-404.
21. Harper JI, Ahmed I, Barclay G, et al. Cyclosporin for severe childhood dermatitis: short course versus continuous therapy. Br J Dermatol 2000; 142:52-58.
22. Granlund H, Erkko P, Sinisalo M, Reitamo S. Cyclosporin in atopic dermatitis: time to relapse and effect of intermittent therapy. Br J Dermatol 1995; 132:106-112.
23. Ellis CN, Battu M. Cyclosporine in the treatment of severe psoriasis. In: Weinstein GD, Gottlieb AB, editors. Therapy of moderate-to-severe psoriasis, 2nd ed. New York: Marcel Dekker; 2003. pp. 151-178.
24. Cather JC, Abramovits W, Menter A. Cyclosporine and tacrolimus in dermatology. Dermatol Clin 2001; 19:119-137; ix.
25. Gottlieb AB, Griffiths CE, Ho VC, et al., Multi-Centre Investigator Group. Oral pimecrolimus in the treatment of moderate to severe chronic plaque-type psoriasis: a double-blind, multicentre, randomized, dose-finding trial. Br J Dermatol 2005; 152:1219-1227.
26. Wolff K, Fleming C, Hanifin J, et al., Multicentre Investigator Group. Efficacy and tolerability of three different doses of oral pimecrolimus in the treatment of moderate to severe atopic dermatitis: a randomized controlled trial. Br J Dermatol 2005; 152:1296-1303.
27. Simpson E, Hanifin J. Atopic dermatitis. J Am Acad Dermatol 2005; 53:115-128.
28. Meggitt SJ, Reynolds NJ. Azathioprine fro atopic dermatitis. Clin Exp Dermatol 2001; 26:369-375.
29. Berth-Jones J, Takwale A, Tan E, et al. Azathioprine in severe adult atopic dermatitis: a double-blind, placebo controlled, cross-over trial. Br J Dermatol 2002; 147:324-330.
30. Buckley DA, Baldwin P, Rogers S. The use of azathioprine in severe adult atopic eczema. J Eur Acad Dermatol Venereol 1998; 11:137-140.
31. Kuanprasert N, Herbert O, Barnetson RS. Clinical improvement and significant reduction of total serum IgE in patients suffering from severe atopic dermatitis treated with oral azathioprine. Australas J Dermatol 2002; 43:125-127.
32. Younger IR, Harris DW, Colver GB. Azathioprine in dermatology. J Am Acad Dermatol 1998; 39:121-123.
33. Meggitt SJ, Gray JC, Reynolds NJ. Azathioprine dosed by thiopurine methyltransferase activity for moderate-to-severe atopic eczema: a double-blind, randomised controlled trial. Lancet 2006; 367:839-846.
34. Neuber K, Schwartz I, Itschert G, Dieck AT. Treatment of atopic eczema with oral mycophenolate mofetil. Br J Dermatol 2000; 143:385-391.
35. Grundmann-Kollman M, Podda M, Oscsendorf F, et al. Mycophenolate mofetil is effective in the treatment of atopic dermatitis. Arch Dermatol 2001; 137: 870-873.
36. Yamuachi PS, Rizk D, Kormeili T, et al. Current systemic therapies for psoriasis: where are we now? J Am Acad Dermatol 2003; 49 (Suppl):S66-S77.
37. Egan CA, Rallis TM, Meadows KP, Krueger GG. Low-dose oral methotrexate treatment for recalcitrant palmoplantar pompholyx. J Am Acad Dermatol 1999; 40:612-614.
38. Shaffrali FC, Cover GB, Messenger AG, Gawkrodger DJ. Experience with low-dose methotrexate for the treatment of eczema in the elderly. J Am Acad Dermatol 2003; 48:417-419.
39. Goujon C, Berard F, Dahel K, et al. Methotrexate for the treatment of adult atopic dermatitis. Eur J Dermatol 2006; 16:155-158.
40. Meagher LJ, Wines NY, Cooper AJ. Atopic dermatitis: review of immunopathogenesis and advances in immunosuppressive therapy. Australas J Dermatol 2002; 43:247-254.
41. Yamauchi PS, Rizk D, Kormeili T, et al. Systemic retinoids. In: Weinstein GD, Gottlieb AB, editors. Therapy of moderate-to-severe psoriasis. New York: Marcel Dekker; 2003. pp. 137-150.
42. Thestrup-Pedersen K, Andersen KE, Menne T, Veien NK. Treatment of hyperkeratotic dermatitis of the palms (eczema keratoticum) with oral acitretin: a single-blind placebo-controlled study. Acta Derm Venereol 2001; 81:353-355.
43. Reinus JF, Persky S, Burkiewicz JS, et al. Severe liver injury after treatment with the leukotriene receptor antagonist zafirlukast. Ann Intern Med 2000; 133:964-968.
44. Pei AY, Chan HH, Leung TF. Montelukast in the treatment of children with moderate-to-severe atopic dermatitis: a pilot study. Pediatr Allergy Immunol 2001; 12:154-158.
45. Capella GL, Grigerio E, Altomare G. A randomized trial of leukotriene receptor antagonist montelukast in moderate-to-severe atopic dermatitis of adults. Eur J Dermatol 2001; 11:209-213.
46. Yanase DJ, David-Bajar K. The leukotriene antagonist montelukast as a therapeutic agent for atopic dermatitis. J Am Acad Dermatol 2001; 44:89-93.
47. Woodmanase DP, Simon RA. A pilot study examining the role of zileuton in atopic dermatitis. Ann Allergy Asthma Immunol 1999; 83:548-552.
48. Stevens SR, Hanifin JM, Hamilton T, et al. Long-term effectiveness and safety of recombinant human interferon gamma therapy for atopic dermatitis despite unchanged serum IgE levels. Arch Dermatol 1998; 134:799-804.
49. DiCarlo J, McCall C. Pharmacologic alternatives for severe atopic dermatitis. Int J Dermatol 2001; 40:82-88.
50. Jolles S. A review of high-dose intravenous immunoglobulin treatment for atopic dermatitis. Clin Exp Dermatol 2002; 27:3-7.
51. Jolles S, Hughes J. Use of IGIV in the treatment of atopic dermatitis, urticaria, scleromyxedema, pyoderma gangrenosum, psoriasis, and pretibial myxedema. Int Immunopharmacol 2006; 6:579-591; Epub 2005 Dec 13.
52. Buka RL, Resh B, Roberts B, et al. Etanercept is minimally effective in 2 children with atopic dermatitis. J Am Acad Dermatol 2005; 53:358-359.
53. Pua VS, Barnetson RS. Recent developments in the treatment of adult atopic dermatitis. Australas J Dermatol 2006; 47:84-89.
54. D'Amato G, Oldani V, Donner CF. Anti-IgE monoclonal antibody: a new approach to the treatment of allergic respiratory diseases. Monaldi Arch Chest Dis 2003; 59:25-29.
55. Scheinfeld N. Omalizumab: a recombinant humanized monoclonal IgEblocking antibody. Dermatol Online J 2005; 11:2.
56. Lane JE, Cheyney JM, Lane TN, et al. Treatment of recalcitrant atopic dermatitis with omalizumab. J Am Acad Dermatol 2006; 54:68-72; Epub 2005 Nov 28.
57. Krathen RA, Hsu S. Failure of omalizumab for treatment of severe adult atopic dermatitis. J Am Acad Dermatol 2005; 53:338-340.
58. Lever R, Hadley K, Downey D, Mackie R. Staphylococcus colonization in atopic dermatitis and the effect of topical mupirocin therapy. Br J Dermatol 1988; 119:189-198.
59. Leung DYM, Bieber T. Atopic dermatitis. Lancet 2003; 361:151-160.
60. Bork K, Brauninger W. Increasing incidence of eczema herpeticum: analysis of seventy-five cases. J Am Acad Dermatol 1988; 19:1024-1029.
61. Nissen D, Petersen LJ, Esch R, et al. IgE-sensitisation to cellular and culture filtrates of fungal extracts in patients with atopic dermatitis. Ann Allergy Asthma Immunol 1998; 81:247-255.
62. Krutmann J. Phototherapy for atopic dermatitis. Clin Exp Dermatol 2000; 25:552-558.
63. Reynolds NJ, Franklin V, Gray JC, et al. Narrow-band ultraviolet B and broadband ultraviolet A phototherapy in adult atopic eczema: a randomized controlled trial. Lancet 2001; 357:2012-2016.
64. Abeck D, Schmidt T, Fesq H, et al. Long-term efficacy of medium-dose UVA1 phototherapy in atopic dermatitis. J Am Acad Dermatol 2000; 42:254-257.
65. Krutmann J, Deipgen TL, Luger TA, et al. High-dose UVA1 therapy for atopic dermatitis: results of a multicenter trial. J Am Acad Dermatol 1998; 38:589-593.
66. Morison WL, Parrish J, Fitzpatrick TB. Oral psoralen photchemotherapy of atopic eczema. Br J Dermatol 1978; 98:25-30.
67. Jekler J, Larko O. UVA solarium versus UVB phototherapy of atopic dermatitis: a paired-comparison study. Br J Dermatol 1991; 125:569-572.
68. Morris AD, Salhan EM. Maintenance psoralen plus ultraviolet A therapy: does it have a role in the treatment of severe atopic eczema? Br J Dermatol 2002; 146:705-707.
69. Lebwohl M, Ali S. Treatment of psoriasis Part 1 Topical therapy and phototherapy. J Am Acad Dermatol 2001; 45:487-498.
70. Breneman DL, Dunlap FE, Monroe EW, et al. Doxepin cream relieves eczema-associated pruritus within 15 min and is not accompanied by a risk of rebound upon discontinuation. J Dermatol Treatment 1997; 8:161-168.
71. Drake LA, Cohen L, Gillies R, et al. Pharmacokinetics of doxepin in subjects with pruritic atopic dermatitis. J Am Acad Dermatol 1999; 41 (2 Pt 1):209-214.
72. Burkhart CG, Burkhart HR. Contact irritant dermatitis and antipruritic agents: the need to address the itch. J Drugs Dermatol 2003; 2:143-146.
73. Scholzen TE, Steinhoff M, Bonaccorsi P, et al. Neutral endopeptidase terminates substance P-induced inflammation in allergic contact dermatitis. J Immunol 2001; 166:1285-1291.
74. Staniek V, Liebich C, Vocks E, et al. Modulation of cutaneous SP receptors in atopic dermatitis after UVA irradiation. Acta Derm Venereol 1988; 78: 92-94.
75. Mohammadian P, Andersen OK, Arendt-Nielsen L. Correlation between local vascular and sensory changes following tissue inflammation induced by repetitive application of topical capsaicin. Brain Res 1998; 792:1-9.
76. Tazorac gel [package insert]. Irvine, CA: Allergan, 1998.
77. Tazorac cream [package insert]. Irvine, CA: Allergan, 2001.
78. Hanifin JM, Stevens V, Sheth P, Breneman D. Novel treatment of chronic severe hand dermatitis with bexarotene gel. Br J Dermatol 2004; 150:545-553.
79. Thami GP, Sarkar R. Coal tar: past, present and future. Clin Exp Dermatol 2002; 27:99-103.
80. Munkvad M. A comparative trial of clinitar versus hydrocortisone cream in the treatment of eczema. Br J Dermatol 1989; 121:763-766.
81. Sarto F, Zordan M, Tomanin R, et al. Chromosomal alterations in peripheral blood lymphocytes, urinary mutagenicity and excretion of polycyclic aromatic hydrocarbon in six psoriatic patients undergoing coal tar therapy. Carcinogenesis 1989; 10:329-334.
82. Stern RS, Zierler S, Parrish JA. Skin carcinoma in patients with psoriasis treated with topical tar and artificial ultraviolet radiation. Lancet 1980; 1:732-735.
83. Maughan WZ, Muller SA, Perry HO, et al. Incidence of skin cancers in patients with atopic dermatitis treated with coal tar. A 25-year follow-up study. J Am Acad Dermatol 1980; 3:612-615.
84. Pion IA, Koenig KL, Lim HW. Is dermatologic usage of coal tar carcinogenic? A review of the literature. Dermatol Surg 1995; 21:227-231.
85. Zackheim HS. Should coal tar products carry cancer warnings? Cutis 2004; 73:333-334.
86. Grewe S, Chan SC, Hanifin JM. Elevated leukocyte cyclic AMP-phosphodiesterase in atopic disease: a possible mechanism for cyclic AMP-agonist hyposresponsiveness. J Allergy Clin Immunol 1982; 70:452-457.
87. Hanifin JM, Chan S. Biochemical and immunologic mechanisms in atopic dermatitis: new targets for emerging therapies. J Am Acad Dermatol 1999; 41:72-77.
88. Hanifin J, Chan S, Cheng J. Type 4 phosphodiesterase inhibitors have clinical and in vitro antiemerging therapies. J Am Acad Dermatol 1999; 41:72-77.
89. Venkatraman MS, Chittiboyina A, Meingassner J, et al. Alpha-Lipoic acid-based PPARfamma agonists for treating inflammatory skin diseases. Arch Dermatol Res 2004; 296:97-104.
90. Protopic [package insert]. Deerfield, IL: Fujisawa Healthcare, 2002.
91. Witman PM. Topical therapies for localized psoriasis. Mayo Clin Proc 2001; 76:943-949.
92. Elidel Cream [package insert]. East Hanover, NJ: Novartis Pharmaceutical, 2003.
93. Kapp A, Papp K, Bingham A, et al. Long-term management of atopic dermatitis in infants with topical pimecrolimus, a nonsteroid anti-inflammatory drug. J Allergy Clin Immunol 2002; 110:277-284.
94. Wahn U, Bos JD, Goodfield M, et al. Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children. Pediatrics 2002; 110 (1 Pt 1):e2.
95. Eichenfield LF, Lucky AW, Boguniewicz M, et al. Safety and efficacy of pimecrolimus (ASM981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescents. J Am Acad Dermatol 2002; 46:495-504.
96. Ho VC, Gupta A, Kaufmann R, et al. Safety and efficacy of nonsteroid pimecrolimus cream 1% in the treatment of atopic dermatitis in infants. J Pediatr 2003; 142:155-162.
97. Luger T, Van Leent EJ, Graeber M, et al. SDZ ASM 981: an emerging safe and effective treatment for atopic dermatitis. Br J Dermatol 2001; 144:788-794.
98. Reitamo S, Rustin M, Ruzicka T, et al. Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone butyrate ointment in adult patients with atopic dermatitis. J Allergy Clin Immunol 2002; 109:547-555.
99. Reitamo S, Van Leent EJM, Ho V, et al. Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone acetate ointment in children with atopic dermatitis. J Allergy Clin Immunol 2002; 109:539-546.
100. Reitamo S, Harper J, Bos JD, et al. 0.03% Tacrolimus ointment applied once or twice daily is more efficacious than 1% hydrocortisone acetate in children with moderate to severe atopic dermatitis: results of a randomized double-blind controlled trial. Br J Dermatol 2004; 150:554-562.
101. Harper J, Green A, Scott G, et al. First experience of topical SDZ ASM 981 in children with atopic dermatitis. Br J Dermatol 2001; 144:781-787.
102. Hanifin JM, Ling MR, Langley R, et al. Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: part I. Efficacy. J Am Acad Dermatol 2001; 44 (1 Suppl):S28-S38.
103. Paller A, Eichenfield LF, Leung DY, et al. A 12-week study of tacrolimus ointment for the treatment of atopic dermatitis in pediatric patients. J Am Acad Dermatol 2001; 44 (1 Suppl):S47-S57.
104. Boguniewicz M, Fiedler VC, Raimer S, et al. A randomized, vehicle-controlled trial of tacrolimus ointment for treatment of atopic dermatitis in children. Pediatric Tacrolimus Study Group. J Allergy Clin Immunol 1998; 102 (4 Pt 1):637-644.
105. Ruzicka T, Bieber T, Schopf E, et al. A short-term trial of tacrolimus ointment for atopic dermatitis. European Tacrolimus Multicenter Atopic Dermatitis Study Group. N Engl Med 1997; 337:816-821.
106. Kang S, Lucky AW, Pariser D, et al. Long-term safety and efficacy of tacrolimus ointment for the treatment of atopic dermatitis in children. J Am Acad Dermatol 2001; 44 (1 Suppl):S58-S64.
107. Reitamo S, Wollenberg A, Schopf E, et al. Safety and efficacy of 1 year of tacrolimus ointment monotherapy in adults with atopic dermatitis. The European Tacrolimus Ointment Study Group. Arch Dermatol 2000; 136:999-1006.
108. Hanifin JM, Leung DY, Paller A, et al. Tacrolimus ointment monotherapy is safe and effective for the long-term treatment of atopic dermatitis in pediatric patients. Presented at the American Academy of Allergy Asthma and Immunology 60th Anniversary Meeting; 7-12 March 2003; Denver, CO [poster 244].
109. Koo JY, Fleisher A, Abramovits W, et al. Tacrolimus is safe and effective in the treatment of atopic dermatitis: results in 8000 patients. J Am Acad Dermatol 2005; 53:S195-S205. Tacrolimus ointment monotherapy in nearly 8000 pediatric and adult patients led to continuous improvement in atopic dermatitis and revealed no change in the safety profile reported in previous clinical trials.
110. Koo JY, Fleischer A, Pariser D, et al. Tacrolimus ointment 0.1% is safe and effective in the treatment for atopic dermatitis: final results of a large (over 7000 patients) open-label study. Presented at the American Academy of Dermatology Conference; 21-26 March 2003; San Francisco, CA [poster P22].
111. Hanifin JM, Thurston M, Omoto M, et al. The eczema and severity index (EASI): assessment of reliability in atopic dermatitis. EASI Evaluator Group. Exp Dermatol 2001; 10:11-18.
112. Abramovits W, Hung P, Tong K. The efficacy and economics of topical calcineurin inhibitors for the treatment of atopic dermatitis. Am J Clin Dermatol (in press). A thorough discussion of topical calcineurin inhibitors in regards to their safety and efficacy, and as a cost-effective treatment option compared with branded corticosteroids and previous standards of care. Evidence showing the positive effects of these agents on the quality of life of patients and their caregivers is presented.
113. Niwa Y, Terashima T, Sumi H. Topical application of the immunosuppressant tacrolimus accelerates carcinogenesis in mouse skin. Br J Dermatol 2003; 149:960-967.
114. Lubbe J, Sorg O. Tacrolimus ointment and skin carcinogenesis in the DMBA/TPA model in mice. Br J Dermatol 2004; 151:1275-1276.
115. Allen A, Siegfried E, Silverman R, et al. Significant absorption of topical tacrolimus in 3 patients with Netherton syndrome. Arch Dermatol 2001; 137:747-750.
116. Langeland T, Engh V. Topical use of tacrolimus and squamous cell carcinoma on the the penis. Br J Dermatol 2005; 152:183-185.
117. Cho M, Puma I, Nguyen D, et al. Development of Kaposi's sarcoma in an AIDs patient after treatment with topical tacrolimus. J Am Acad Dermatol 2004; 50:149-150.
118. Bunker CB, Neill S, Staughton RC. Topical tacrolimus, genital lichen sclerosus, and risk of squamous cell carcinoma. Arch Dermatol 2004; 140:1169.
119. Ellis D, Jaffe R, Green M, et al. Epstein-Barr virus-related disorders in children undergoing renal transplantation with tacrolimus-based immunosuppression. Transplantation 1999; 68:997-1003.
120. Harper J, Smith C, Rubins A, et al. A multicenter study of the pharmokinetics of tacrolimus ointment after first and repeated application to children with atopic dermatitis. J Invest Dermatol 2005; 124:695-699.
121. Naylor M, Elmets CA, Rico MJ, Zheng S. Treatment with topical tacrolimus is not associated with an increase in nonmelanoma skin cancer. Presented at the 12th Congress of the European Academy of Dermatology and Venereology; 15-18 October 2003; Barcelona, Spain [abstract].
122. Berger T, Duvic M, Van Voorhees A, et al. The use of topical calcineurin inhibitors in dermatology: safety concerns. J Am Acad Dermatol 2006; 54:818-823. A full recount of the safety issues surrounding the use of topical calcineurin inhibitors with a discussion of available evidence. Emphasis is placed on the inconclusive nature of the available data.
123. Ormerod AD. Topical tacrolimus and pimecrolimus and the risk of cancer: how much cause for concern? Br J Dermatol 2005; 153:701-705. Concerns resulting from the recent FDA announcement regarding a theoretical risk of cancer associated with topical calcineurin inhibitors are addressed.
124. Monder C, White PC. 11 beta hydroxysteroid dehydrogenase. Vitam Horm 1993; 47:187-271.
125. MacKenzie MA, Hoefnagels WH, Jansen RW, et al. The influence of glycyrrhetinic acid on plasma cortisol and cortisone in healthy volunteers. J Clin Endocrinol Metab 1990; 70:1637-1643.
126. Abramovits W, Boguniewicz M. A multicenter, randomized, vehicle-controlled clinical study to examine the efficacy and safety of MAS063DP (Atopiclair) in the management of mild to moderate atopic dermatitis in adults. J Drugs Dermatol 2006; 5:236-244. The successful management of atopic dermatitis may require a multiprong approach that includes a permutational paradigm of systemic agents, phototherapy, topical agents with immunoregulatory and barrier repair functions, and preventative educational and psycho/social intervention. Clinical studies have recently demonstrated the efficacy and safety of MAS063DP (Atopiclair) cream in the treatment of mild to moderate atopic dermatitis, and in irritant contact dermatitis in adult and pediatric populations. Integration of this agent into current treatment paradigms may allow for greater sparing of topical corticosteroid-related adverse effects.
127. Abramovits W, Gover M, Gupta A. Atopiclair nonsteroidal cream. Skinmed 2005; 4:69.
128. Cimaz R. Efficacy and safety of Atopiclair in pediatric dermatoses: preliminary findings from an open pilot study. Proceedings of the Atopiclair Trial Milan; April 2002; Milan, Italy. pp. 1-7.
129. Belloni G, Pinelli S, Veraldi S. A randomized, double-blind, vehicle controlled study to evaluate the efficacy and safety of MAS063DP (Atopiclair) in the treatment of mild to moderate atopic dermatitis. Eur J Dermatol 2005; 15:31-36.
130. Zhai H, Villarama C, Hafeez Z, et al. Efficacy of a topical agent, MAS063D (Atopiclair), in the treatment of sodium lauryl sulphate-induced irritant contact dermatitis: a double-blind, vehicle-controlled study. Exog Dermatol 2003; 2:301-330.
131. MimyX cream [package insert]. Coral Gables, FL: Steifel Laboratories.
132. Jorizzo J. Lamellar preparations as adjunctive therapy in the treatment of atopic dermatitis. Presented at the 63rd Annual Meeting of the American Academy of Dermatology; 18-22 February 2005; New Orleans, LA [poster 721].
133. Jorizzo JL. The palmitoylethanolamide family: a new treatment choice for atopic dermatitis? Presented at the 63rd Annual Meeting of the Amercian Academy of Dermatology; 18-22 February 2005; New Orleans, LA [poster P729].
134. Kemeny L. The effect of Physiogel A.I., an endogenous phospholipids metabolite containing topical product, on the lipid contents of the human skin. Presented at the 64th Annual Meeting of the American Academy of Dermatology; March 2006; San Francisco, CA [abstract].
135. Eberlein-Koenig B, Eicke C, et al. Adjuvant treatment of atopic eczema: assessment of an emollient containing N-palmitoylethanolamine (ATOPA). Presented at the 64th Annual Meeting of the American Academy of Dermatology; March 2006; San Francisco, CA [abstract].
136. Llorca MA, Dorado Bris JM, Saenz de Santamaria MC, et al. Evaluation of the activity of a moisturizing and restoring-action preparation, with lamellar structure, as adjuvant in the treatment of atopic dermatitis and xerotic skin. Rev Intern Dermatol Dermocosm 2003; 6:425-430.
137. Lamber DM, Vandevoorde S, Jonsson K-O, et al. The palmitoylethanolamide family: a new class of anti-inflammatory agents. Curr Med Chem 2002; 9:663-674.
138. Matias I, Pochard P, Orlando P, et al. Presence and regulation of the endocannabinoid system in human dendritic cells. Eur J Biochem 2002; 269:3771-3778.
139. Kemeny L. Comparative study of S236 cream and hydrocortisone 1% in patients with atopic dermatitis. Presented at the 63rd Annual Meeting of the American Academy of Dermatology; 18-22 February 2005; New Orleans, LA [poster 708].
140. Grove GL, Zerweck C. Efficacy of S236 (MimyX cream), a medical device cream, in promoting barrier repair of razor-induced skin trauma. Presented at the 64th Annual Meeting of the American Academy of Dermatology; March 2006; San Francisco, CA.
141. Laumann A, Lai S, Lucky A, et al. The efficacy and safety of MimyX Cream in reducing the risk of relapse in atopic dermatitis. Presented at the 67th Annual SID Meeting; 3-6 May 2006; Philadelphia, PA.
142. Abramovits W, Perlmutter A. MimyX Cream. Skinmed 2006; 29-30.
143. SBR-Lipocream [package insert]. Ferndale, MI: Ferndale Laboratories.
144. TheraSeal [package insert]. San Antonio, TX: DPT Laboratories, Ltd.
145. Lucky AW, Leach AD, Laskarzewski P, et al. Use of an emollient as a steroid-sparing agent in the treatment of mild to moderate atopic dermatitis in children. Pediatr Dermatol 1997; 14:321-322.
146. Imokawa G, Abe A, Jin K, et al. Decreased level of ceramides in statum corneum of atopic dermatitis. An etiologic factor in atopic dry skin? J Invest Dermatol 1991; 96:523-526.
147. Rawlings AV, Davies A, Carlomusto M, et al. Effect of lactic acid isomers on keratinocyte ceramide synthesis, stratum corneum barrier function. Arch Dermatol Res 1996; 288:383-390.
148. Loden M. Urea-containing moisturizers influence barrier properties of normal skin. Arch Dermatol Res 1996; 288:103-107.
149. Kantor I, Milbauer J, Posner M, et al. Efficacy and safety of emollients as adjunctive agents in topical corticosteroid therapy for atopic dermatitis. Today Ther Trend 1993; 11:157-166.
150. Goldstein AM, Abramovits W. Ceramides and the stratum corneum: structure, function and new methods to promote repair. Int J Dermatol 2003; 42:256-259.
151. Lebwohl M, Herrmann LG. Impaired skin barrier function in dermatologic disease and repair with moisturization. Cutis 2005; 76 (Suppl 6):7-12.
152. CeraVe [package insert]. Fort Worth, TX: Coria Laboratories.
153. Ceragenix Pharmaceuticals. Ceragenix receives 510k clearance of Epi-Ceram for the treatment of atopic dermatitis and other skin disorders. Press release 12 April 2006. Denver, CO: Ceragenix Pharmaceuticals. www.ceragenix.com.
154. Palmer CN, Irvine AD, Terron-Kwiatkowski A, et al. Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. Nat Genet 2006; 38:441-446.
155. Sugiura H, Ebise H, Tazawa T, et al. Large-scale DNA microassay analysis of atopic skin lesions shows overexpression of an epidermal differentiation gene cluster in the alternative pathway and lack of protective gene expression in the cornified envelope. Br J Dermatol 2005; 152:146-149.
156. Vince G. Skin faults linked to allergic disorders. New Scientist 2006; 6 May: 18.
157. Ceragenix Pharmaceuticals. Ceragenix compound demonstrates activity against MRSA biofilm. Newsletter 8 May 2006. Denver, CO: Ceragenix Pharmaceuticals. www.ceragenix.com.
158. Melnik B. Disturbances of antimicrobial lipids in atopic dermatitis. J Dtsch Dermatol Ges 2006; 4:114-123.
159. Takigawa H, Nakagawa H, Kuzukawa M, et al. Deficient production of hexadecenoic acid in the skin is associated in part with the vulnerability of atopic dermatitis patients to colonization by Staphylococcus aureus. Dermatology 2005; 211:240-248.
160. Mayser P, Kupfer J, Nemetz D, et al. Treatment of head and neck dermatitis with ciclopiroxolamine cream - results of a double-blind, placebo-controlled study. Skin Pharmacol Physiol 2006; 19:153-158.
161. Cutivate [package insert]. Duluth, GA: PharmaDerm.
162. Heymann WR. Intramuscular triamcinolone. J Am Acad Dermatol 2006; 54:866-867.